Vanguard Capital Wealth Advisors
IBRX icon

Vanguard Capital Wealth Advisors’s ImmunityBio IBRX Stock Holding History

Vanguard Capital Wealth Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$76.7K – 146
2026
Q1 		$76.7K Buy
+10,000
New +$68.5K 0.07% 115

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Wealth Advisors's IBRX Position: Q2 2026 in Review

Vanguard Capital Wealth Advisors sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 10,000 shares — an estimated $76.7K sold.

Vanguard Capital Wealth Advisors first reported a position in IBRX in Q1 2026 and held it in 1 quarter. The position peaked at $76.7K in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Vanguard Capital Wealth Advisors reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
  • Vanguard Capital Wealth Advisors sold 10,000 ImmunityBio shares in Q2 2026, an estimated $76.7K.
  • Vanguard Capital Wealth Advisors first reported a position in ImmunityBio in Q1 2026 and held it in 1 quarter.
  • Vanguard Capital Wealth Advisors's ImmunityBio position peaked at $76.7K in Q1 2026.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Vanguard Capital Wealth Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.